The Limited Population Pathway for Antibacterial and Antifungal Drugs Archives • NCK Pharma

Case Study: USFDA The Limited Population Pathway and approval of Arikayce

Posted on03 Oct 2018

TagsArikayce, LAPD, The Limited Population Pathway for Antibacterial and Antifungal Drugs, USFDA new drugs approval

Comments0

The US Food and Drug Administration late Friday granted accelerated approval of Arikayce (amikacin liposome inhalation suspension), developed by US biotech Insmed,...